Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells have a deleterious impact on clinical responses to therapeutic antibodies. Myeloid checkpoints, which negatively regulate macro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Chilam, Lustig, Marta, Baumann, Niklas, Valerius, Thomas, van Tetering, Geert, Leusen, Jeanette H. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295600/
https://www.ncbi.nlm.nih.gov/pubmed/35865547
http://dx.doi.org/10.3389/fimmu.2022.932155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295600/
https://www.ncbi.nlm.nih.gov/pubmed/35865547
http://dx.doi.org/10.3389/fimmu.2022.932155

Ejemplares similares